Advertisement

Clinical Syndromes: Pneumocystis

  • Peter-Michael RathEmail author
Chapter

Abstract

Pneumocystis jirovecii is an opportunistic (fungal) pathogen, causing live threatening pulmonary infections in immunosuppressed patients. The diagnosis is based on clinical symptoms (fever, progressive dyspnea, dry cough), radiological findings (diffuse bilateral intestinal infiltrates), and laboratory abnormalities (hypercapnia, elevated lactate dehydrogenase, elevated (1-3)-ß-D-Glucan). Because these signs are more or less unspecific, the laboratory detection of the pathogen is essential. Since the organism is not cultivable on artificial media the diagnosis is based on the microscopic detection of cysts or trophozoites in deep respiratory material. Microscopic methods are replaced more and more by PCR systems. Because of a high incidence of colonization in asymptomatic individuals, results of quantitative assays are more helpful for clinicians than those of qualitative tests. First choice for prophylaxis and treatment is trimethoprim/sulfamethoxazole.

References

  1. 1.
    Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Sci Transl Med 4:165rv13PubMedCrossRefGoogle Scholar
  2. 2.
    Durand-Joly I, Aliouat EM, Recourt C, Guyot K, François N, Wauquier M, Camus D, Dei-Cas E (2002) Pneumocystis carinii f. sp. hominis is not infectious for SCID mice. J Clin Microbiol 40:1862–1865PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Aliouat-Denis C-M, Chabé M, Demanche C, Aliouat EM, Viscogliosi E, Guillot J, Delhaes L, Dei-Cas E (2008) Pneumocystis species, coevolution and pathogenic power. Infect Genet Evol 8:708–726PubMedCrossRefGoogle Scholar
  4. 4.
    Aliouat-Denis C-M, Martinez A, Aliouat EM, Pottier M, Gantois N, Dei-Cas E (2009) The Pneumocystis life cycle. Mem Inst Oswaldo Cruz 104:419–426PubMedCrossRefGoogle Scholar
  5. 5.
    Ma L, Huang D-W, Cuomo CA, Sykes S, Fantoni G, Das B, Sherman BT, Yang J, Huber C, Xia J, Davey E, Kutty G, Bishop L, Sassi M, Lempicki RA, Kovacs JA (2013) Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis. FASEB J 27:1962–1972PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Stringer JR, Beard CB, Miller RF (2009) Spelling Pneumocystis jirovecii. Emerg Infect Dis 15:506PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Chabé M, Aliouat-Denis C-M, Delhaes L, Aliouat EM, Viscogiosi E, Dei-Cas E (2011) Pneumocystis: from a doubtful unique entity to a group of highly diversified fungal species. FEMS Yeast Res 11:2–17PubMedCrossRefGoogle Scholar
  8. 8.
    Kelly MN, Shellito JD (2010) Current understanding of Pneumocystis immunology. Future Microbiol 5:43–65PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Cushion MT, Linke MJ, Ashbaugh A, Sesterhenn T, Collins MS, Lynch K, Brubaker R, Walzer PD (2010) Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 5:e8524PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Martinez A, Halliez MCM, Aliouat EM, Chabé M, Standaert-Vitse A, Fréalle E, Gantois N, Pottier M, Pinon A, Dei-Cas E, Aliouat-Denis C-M (2013) Growth and airborne transmission of cell-sorted life cycle stages of Pneumocystis carinii. PLoS ONE 8:e79958PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Calderón EJ (2009) Epidemiology of Pneumocystis infection in humans. J Mycol Méd 19:270–275CrossRefGoogle Scholar
  12. 12.
    Roux A, Gonzales F, Roux M, Mehrad M, Menotti J, Zahar J-R, Tadros V-X, Azoulay E, Brillet P-Y, Vincent F (2014) Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients. Méd Mal Infect 44:185–198PubMedCrossRefGoogle Scholar
  13. 13.
    Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, Phin N (2013) Increasing Pneumocystis pneumonia, England, UK, 2000–2010. Emerg Infect Dis 19:386–392PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Ponce CA, Gallo M, Bustamante R, Vargas SL (2010) Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 50:347–353PubMedCrossRefGoogle Scholar
  15. 15.
    Morris A, Wei K, Afshar K, Huang L (2008) Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 197:10–17PubMedCrossRefGoogle Scholar
  16. 16.
    Vargas SL, Ponce CA, Gallo M, Pérez F, Astorga J-F, Bustamante R, Chabé M, Durand-Joly I, Iturra P, Miller RF, Aliouat EL, Dei-Cas E (2013) Near-universal prevalence of Pneumocystis and associated Increase in mucus in the lungs of infants with sudden unexpected death. Clin Infect Dis 56:171–179PubMedCrossRefGoogle Scholar
  17. 17.
    Fritsche C, Ghanem H, Koball S, Mueller-Hilke B, Reisinger EC (2017) High Pneumocystis jirovecii colonization rate among haemodialysis patients. Infect Dis 49:132–136CrossRefGoogle Scholar
  18. 18.
    Fritzsche C, Riebold D, Fuehrer A, Mitzner A, Klammt S, Mueller-Hilke B, Reisinger EC (2013) Pneumocystis jirovecii colonization among renal transplant recipients. Nephrology 18:382–387PubMedCrossRefGoogle Scholar
  19. 19.
    Morris A, Netravali M, Kling HM, Shipley T, Ross T, Sciurba FC, Norris KA (2008) Relationship of Pneumocystis antibody response to severity of chronic obstructive pulmonary disease. Clin Infect Dis 47:e64–e68PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Green HD, Bright-Thomas RJ, Mutton KJ, Guiver M, Jones AM (2016) Increased prevalence of Pneumocystis jirovecii colonization in acute pulmonary exacerbations of cystic fibrosis. J Infect 73:1–7PubMedCrossRefGoogle Scholar
  21. 21.
    Yiannakis EP, Boswell TC (2016) Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect 93:1–8PubMedCrossRefGoogle Scholar
  22. 22.
    Siegel JD, Rhinehart E, Jackson M, Chiarello L; The Healthcare Infection Control Practices Advisory Committee (2007) Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf
  23. 23.
    LeGal S, Pougnet L, Damiani C, Fréalle E, Guéguen P, Virmaux M, Ansart S, Jaffuel S, Couturaud F, Delluc A, Tonnelier J-M, Castellant P, Le Meur Y, Le Floch G, Todet A, Menotti J, Nevez G (2015) Pneumocystis jirovecii in the air surrounding patients with Pneumocystis pulmonary colonization. Diagn Microbiol Infect Dis 82:137–142CrossRefGoogle Scholar
  24. 24.
    Fong S, Daly KR, Tipirneni R, Jarlsberg LG, Djawe K, Koch JV, Swartzman A, Roth B, Walzer PD, Huang L (2013) Antibody responses against Pneumocystis jirovecii in health care workers over time. Emerg Infect Dis 19:1612–1619PubMedCrossRefGoogle Scholar
  25. 25.
    Valade S, Azoulay E, Damiani C, Derouin F, Totet A, Menotti J (2015) Pneumocystis jirovecii airborne transmission between critically ill patients and health care workers. Intensive Care Med 41:1716–1718PubMedCrossRefGoogle Scholar
  26. 26.
    Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J et al (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100:663–671PubMedCrossRefGoogle Scholar
  27. 27.
    Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S (2016) Pneumocystis pneumonia suspected in 604 non-HIV and HIV patients. Int J Infect Dis 46:11–17PubMedCrossRefGoogle Scholar
  28. 28.
    Ng VL, Yajko DM, Hadley WK (1997) Extrapulmonary pneumocystosis. Clin Microbiol Rev 10:401–418PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Rath P-M, Steinmann J (2014) Update on diagnosis of Pneumocystis pulmonary infections. Curr Fungal Infect Rep 8:227–234CrossRefGoogle Scholar
  30. 30.
    Procop GW, Haddad S, Quinn J, Wilson ML, Henshaw NG, Reller LB, Artymyshyn RL, Katanik MT, Weinstein MP (2004) Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J Clin Microbiol 42:3333–3335PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C (2002) Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 20:982–989PubMedCrossRefGoogle Scholar
  32. 32.
    Schildgen V, Mai S, Khalfaouri S, Lüsebrink J, Pieper M, Tillmann RL, Brockmann M, Schildgen O (2014) Pneumocystis jirovecii can be productively cultured in differentiated CuFi-8 air was cells. MBio 5:e01186–e01114PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    To KKW, Wong SCY, Xu T, Poon RWS, Mok K-Y, Chan JFW, Cheng VCC, Chan K-H, Hung IFN, Yuen K-Y (2013) Use of nasopharyngeal aspirate for diagnosis of Pneumocystis pneumonia. J Clin Microbiol 51:1570–1574PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Sasso M, Chastang-Dumas E, Bastide S, Alonso S, Lechiche C, Bourgeois N, Lachauda L (2016) Performances of four real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol 54:625–630PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Louis M, Guitard J, Jodar M, Ancelle T, Magne D, Lascols O, Hennequin C (2015) Impact of HIV infection status on interpretation of quantitative PCR for detection of Pneumocystis jirovecii. J Clin Microbiol 53:3870–3875PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Esteves F, Calé SS, Badura R, de Boer MG, Maltez F, Calderón EJ, van der Reijden TJ, Márquez-Martin E, Antunes F, Matos O (2015) Diagnosis of Pneumocystis pneumonia: evaluation of four serologic biomarkers. Clin Microbiol Infect 21:379.e1–379.e10CrossRefGoogle Scholar
  37. 37.
    Finkelman MA (2010) Pneumocystis jirovecii infection: cell wall(1→3)-β-D-glucan biology and diagnostic utility. Crit Rev Microbiol 36:271–281PubMedCrossRefGoogle Scholar
  38. 38.
    Theel ES, Doern CD (2013) ß-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol 51:3478–3483PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Karageorgopoulos DE, Qu J-M, Korbila IP, Zhu J-G, Vasileiou VA, Falagas ME (2013) Accuracy of ß-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 19:39–49PubMedCrossRefGoogle Scholar
  40. 40.
    Li W-J, Guo Y-L, Liu T-J, Wang K, Kong J-L (2015) Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-glucan: a bivariate meta-analysis and systematic review. J Thorac Dis 7:2214–2225PubMedPubMedCentralGoogle Scholar
  41. 41.
    Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A (2013) Combined quantification of pulmonary pneumocystis jirovecii DNA and serum (1-3)-D-glucan for differential diagnosis of Pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol 51:3380–3388PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Damiani C, Le Gal S, Goin N, Di Pizio P, Da Costa C, Virmaux M, Bach V, Stéphan-Blanchard E, Nevez G, Totet A (2015) Usefulness of (1,3) ß-D-glucan detection in bronchoalveolar lavage samples in Pneumocystis pneumonia and Pneumocystis pulmonary colonization. J Mycol Méd 25:36–43PubMedCrossRefGoogle Scholar
  43. 43.
    Messiaen PE, Cuyx S, Dejagere T, van der Hilst JC (2017) The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: a systematic review. Transpl Infect Dis 19:e12651CrossRefGoogle Scholar
  44. 44.
    Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJG, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C (2016) ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71:2397–2404PubMedCrossRefGoogle Scholar
  45. 45.
    Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H (2009) Guideline for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR 58(RR04):1–198PubMedGoogle Scholar
  46. 46.
    Maschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P (2016) ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother 71:2405–2413PubMedCrossRefGoogle Scholar
  47. 47.
    Wang L, Liang H, Ye L, Jiang J, Liang B, Hunag J (2016) Adjunctive corticosteroids for the treatment of Pneumocystis jiroveci pneumonia in patients with HIV: A meta-analysis. Exp Ther Med 11:683–687PubMedCrossRefGoogle Scholar
  48. 48.
    Fujikura Y, Manabe T, Kawana A, Kohno S (2017) Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in non-HIV-infected patients: A systematic review and meta-analysis of observational studies. Arch Bronconeumol 53:55–61PubMedCrossRefGoogle Scholar
  49. 49.
    Kamboj M, Weinstock D, Sepkowitz KA (2006) Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis 43:e92–e94PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Medical MicrobiologyUniversity Hospital of EssenEssenGermany

Personalised recommendations